Global Short-acting GLP-1 Therapy Market Research Report 2026(Status and Outlook)

May 2026 | 122 pages | ID: G2A083504126EN
Bosson Research

Abstracts

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Short-acting GLP-1 Therapy competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.Short-acting GLP-1 therapy refers to glucagon-like peptide-1 receptor agonists with brief systemic exposure (hours, not days), taken once- or twice-daily. They blunt post-meal glucose spikes mainly by slowing gastric emptying and enhancing glucose-dependent insulin release; effects on fasting glucose and weight are typically smaller than with weekly, long-acting agents. In 2024, global Short-acting GLP-1 Therapy production reached approximately 92961 K Unit, with an average global market price of around US$ 362 per unit.Market outlook. Short-acting GLP-1 therapies (e.g., twice-daily or once-daily injectable analogs with strong post-prandial glucose effects via gastric-emptying delay) will remain a smaller, more price-sensitive niche versus long-acting weekly incretins, yet they retain strategic roles where prandial control is paramount—add-on to basal insulin, earlier T2D lines in cost-constrained markets, peri-prandial use in inpatient/acute settings, and for patients who poorly tolerate long-acting agents. Over the next 3–5 years, volume growth is expected to be modest in developed markets (offset by switching to weekly or dual agonists) but steadier in emerging regions and payer segments prioritizing lower acquisition cost, with upside from fixed-ratio basal insulin + short-acting GLP-1 combinations targeted at post-meal excursions.Industry chain structure. Upstream includes peptide starting materials (protected amino acids, coupling reagents), solid-phase peptide synthesis capacity, purification (prep HPLC), and device components (disposable pens, safety needles), plus stabilizing excipients. Midstream originators and specialty generics/biosimilars firms formulate immediate-release injections, perform fill-finish into pens/cartridges, and run CMC, device human factors, and stability programs; CMOs/CDMOs increasingly supply peptide API and aseptic filling as capacity scales out of originators. Downstream, endocrinology and primary-care channels, diabetes clinics, and hospital formularies drive demand; payers influence persistence via tiering and step therapy, while retail/mail-order pharmacies and specialty distributors handle fulfillment and device training, with digital diabetes platforms adding adherence nudges and titration guidance.Drivers and constraints. Demand is underpinned by prandial glucose control, rapid titration and reversibility (useful where GI tolerability is a concern), lower ASPs than weekly agents, and broad familiarity of daily pens. Headwinds are substantial: superior weight-loss and cardiometabolic data from once-weekly GLP-1s and next-gen incretin combos; patient preference for less frequent dosing; and growing obesity indications that favor long-acting molecules. Competitive strategies for short-acting players therefore center on value pricing, fixed-ratio co-formulations with basal insulin, hospital and peri-operative protocols, and regional tenders; lifecycle management focuses on pen usability, cold-chain robustness, and real-world evidence in PPG-dominant phenotypes (high CGM time-above-range post meals).Economics and margin profile. Short-acting GLP-1s typically carry lower list prices and higher rebate pressure than weekly peers, but manufacturing costs (shorter peptide chains, simpler devices) are also lower. Prospects. Expect a bifurcated market: in high-income regions, short-acting GLP-1s stabilize as adjuncts for PPG control (often in fixed-ratio or protocolized inpatient use); in cost-sensitive markets, they remain first-line incretin options where weekly analogs are unaffordable or supply-constrained. Manufacturers that pair competitive pricing with reliable supply, user-friendly pens, and evidence in CGM-defined PPG phenotypes can sustain share and healthy—if not peak—margins despite the class’s shift toward long-acting therapies.

The global Short-acting GLP-1 Therapy market size was estimated at USD 33652.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 19.00% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Short-acting GLP-1 Therapy market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Short-acting GLP-1 Therapy market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Short-acting GLP-1 Therapy market.

Global Short-acting GLP-1 Therapy Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

• Sanofi
• AstraZeneca
• Amneal Pharmaceuticals

Market Segmentation (by Type)

• Injection
• Oral

Market Segmentation (by Application)

• Type 2 Diabetes
• Obesity/Weight Management
• Other

Geographic Segmentation

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Short-acting GLP-1 Therapy Market

Overview of the regional outlook of the Short-acting GLP-1 Therapy Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Short-acting GLP-1 Therapy Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Short-acting GLP-1 Therapy, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Short-acting GLP-1 Therapy
1.2 Key Market Segments
  1.2.1 Short-acting GLP-1 Therapy Segment by Type
  1.2.2 Short-acting GLP-1 Therapy Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 SHORT-ACTING GLP-1 THERAPY MARKET OVERVIEW

2.1 Global Market Overview
  2.1.1 Global Short-acting GLP-1 Therapy Market Size (M USD) Estimates and Forecasts (2020-2035)
  2.1.2 Global Short-acting GLP-1 Therapy Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 SHORT-ACTING GLP-1 THERAPY MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Short-acting GLP-1 Therapy Product Life Cycle
3.3 Global Short-acting GLP-1 Therapy Sales by Manufacturers (2020-2025)
3.4 Global Short-acting GLP-1 Therapy Revenue Market Share by Manufacturers (2020-2025)
3.5 Short-acting GLP-1 Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Short-acting GLP-1 Therapy Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Short-acting GLP-1 Therapy Market Competitive Situation and Trends
  3.8.1 Short-acting GLP-1 Therapy Market Concentration Rate
  3.8.2 Global 5 and 10 Largest Short-acting GLP-1 Therapy Players Market Share by Revenue
  3.8.3 Mergers & Acquisitions, Expansion

4 SHORT-ACTING GLP-1 THERAPY INDUSTRY CHAIN ANALYSIS

4.1 Short-acting GLP-1 Therapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF SHORT-ACTING GLP-1 THERAPY MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Short-acting GLP-1 Therapy Market Porter's Five Forces Analysis
  5.6.1 Global Trade Frictions
  5.6.2 U.S. Tariff Policy – April 2025
  5.6.3 Global Trade Frictions and Their Impacts to Short-acting GLP-1 Therapy Market
5.7 ESG Ratings of Leading Companies

6 SHORT-ACTING GLP-1 THERAPY MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Short-acting GLP-1 Therapy Sales Market Share by Type (2020-2025)
6.3 Global Short-acting GLP-1 Therapy Market Size by Type (2020-2025)
6.4 Global Short-acting GLP-1 Therapy Price by Type (2020-2025)

7 SHORT-ACTING GLP-1 THERAPY MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Short-acting GLP-1 Therapy Market Sales by Application (2020-2025)
7.3 Global Short-acting GLP-1 Therapy Market Size (M USD) by Application (2020-2025)
7.4 Global Short-acting GLP-1 Therapy Sales Growth Rate by Application (2020-2025)

8 SHORT-ACTING GLP-1 THERAPY MARKET SALES BY REGION

8.1 Global Short-acting GLP-1 Therapy Sales by Region
  8.1.1 Global Short-acting GLP-1 Therapy Sales by Region
  8.1.2 Global Short-acting GLP-1 Therapy Sales Market Share by Region
8.2 Global Short-acting GLP-1 Therapy Market Size by Region
  8.2.1 Global Short-acting GLP-1 Therapy Market Size by Region
  8.2.2 Global Short-acting GLP-1 Therapy Market Size by Region
8.3 North America
  8.3.1 North America Short-acting GLP-1 Therapy Sales by Country
  8.3.2 North America Short-acting GLP-1 Therapy Market Size by Country
  8.3.3 U.S. Market Overview
  8.3.4 Canada Market Overview
  8.3.5 Mexico Market Overview
8.4 Europe
  8.4.1 Europe Short-acting GLP-1 Therapy Sales by Country
  8.4.2 Europe Short-acting GLP-1 Therapy Market Size by Country
  8.4.3 Germany Market Overview
  8.4.4 France Market Overview
  8.4.5 U.K. Market Overview
  8.4.6 Italy Market Overview
  8.4.7 Spain Market Overview
8.5 Asia Pacific
  8.5.1 Asia Pacific Short-acting GLP-1 Therapy Sales by Region
  8.5.2 Asia Pacific Short-acting GLP-1 Therapy Market Size by Region
  8.5.3 China Market Overview
  8.5.4 Japan Market Overview
  8.5.5 South Korea Market Overview
  8.5.6 India Market Overview
  8.5.7 Southeast Asia Market Overview
8.6 South America
  8.6.1 South America Short-acting GLP-1 Therapy Sales by Country
  8.6.2 South America Short-acting GLP-1 Therapy Market Size by Country
  8.6.3 Brazil Market Overview
  8.6.4 Argentina Market Overview
  8.6.5 Columbia Market Overview
8.7 Middle East and Africa
  8.7.1 Middle East and Africa Short-acting GLP-1 Therapy Sales by Region
  8.7.2 Middle East and Africa Short-acting GLP-1 Therapy Market Size by Region
  8.7.3 Saudi Arabia Market Overview
  8.7.4 UAE Market Overview
  8.7.5 Egypt Market Overview
  8.7.6 Nigeria Market Overview
  8.7.7 South Africa Market Overview

9 SHORT-ACTING GLP-1 THERAPY MARKET PRODUCTION BY REGION

9.1 Global Production of Short-acting GLP-1 Therapy by Region(2020-2025)
9.2 Global Short-acting GLP-1 Therapy Revenue Market Share by Region (2020-2025)
9.3 Global Short-acting GLP-1 Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Short-acting GLP-1 Therapy Production
  9.4.1 North America Short-acting GLP-1 Therapy Production Growth Rate (2020-2025)
  9.4.2 North America Short-acting GLP-1 Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Short-acting GLP-1 Therapy Production
  9.5.1 Europe Short-acting GLP-1 Therapy Production Growth Rate (2020-2025)
  9.5.2 Europe Short-acting GLP-1 Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Short-acting GLP-1 Therapy Production (2020-2025)
  9.6.1 Japan Short-acting GLP-1 Therapy Production Growth Rate (2020-2025)
  9.6.2 Japan Short-acting GLP-1 Therapy Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Short-acting GLP-1 Therapy Production (2020-2025)
  9.7.1 China Short-acting GLP-1 Therapy Production Growth Rate (2020-2025)
  9.7.2 China Short-acting GLP-1 Therapy Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

10.1 Sanofi
  10.1.1 Sanofi Basic Information
  10.1.2 Sanofi Short-acting GLP-1 Therapy Product Overview
  10.1.3 Sanofi Short-acting GLP-1 Therapy Product Market Performance
  10.1.4 Sanofi Business Overview
  10.1.5 Sanofi SWOT Analysis
  10.1.6 Sanofi Recent Developments
10.2 AstraZeneca
  10.2.1 AstraZeneca Basic Information
  10.2.2 AstraZeneca Short-acting GLP-1 Therapy Product Overview
  10.2.3 AstraZeneca Short-acting GLP-1 Therapy Product Market Performance
  10.2.4 AstraZeneca Business Overview
  10.2.5 AstraZeneca SWOT Analysis
  10.2.6 AstraZeneca Recent Developments
10.3 Amneal Pharmaceuticals
  10.3.1 Amneal Pharmaceuticals Basic Information
  10.3.2 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Product Overview
  10.3.3 Amneal Pharmaceuticals Short-acting GLP-1 Therapy Product Market Performance
  10.3.4 Amneal Pharmaceuticals Business Overview
  10.3.5 Amneal Pharmaceuticals SWOT Analysis
  10.3.6 Amneal Pharmaceuticals Recent Developments

11 SHORT-ACTING GLP-1 THERAPY MARKET FORECAST BY REGION

11.1 Global Short-acting GLP-1 Therapy Market Size Forecast
11.2 Global Short-acting GLP-1 Therapy Market Forecast by Region
  11.2.1 North America Market Size Forecast by Country
  11.2.2 Europe Short-acting GLP-1 Therapy Market Size Forecast by Country
  11.2.3 Asia Pacific Short-acting GLP-1 Therapy Market Size Forecast by Region
  11.2.4 South America Short-acting GLP-1 Therapy Market Size Forecast by Country
  11.2.5 Middle East and Africa Forecasted Sales of Short-acting GLP-1 Therapy by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global Short-acting GLP-1 Therapy Market Forecast by Type (2026-2035)
  12.1.1 Global Forecasted Sales of Short-acting GLP-1 Therapy by Type (2026-2035)
  12.1.2 Global Short-acting GLP-1 Therapy Market Size Forecast by Type (2026-2035)
  12.1.3 Global Forecasted Price of Short-acting GLP-1 Therapy by Type (2026-2035)
12.2 Global Short-acting GLP-1 Therapy Market Forecast by Application (2026-2035)
  12.2.1 Global Short-acting GLP-1 Therapy Sales (K MT) Forecast by Application
  12.2.2 Global Short-acting GLP-1 Therapy Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Short-acting GLP-1 Therapy Market Size by Type (M USD)
Table 4. Global Short-acting GLP-1 Therapy Market Size by Application
Table 5. Short-acting GLP-1 Therapy Market Size Comparison by Region (M USD)
Table 6. Global Short-acting GLP-1 Therapy Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Short-acting GLP-1 Therapy Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Short-acting GLP-1 Therapy Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Short-acting GLP-1 Therapy Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Short-acting GLP-1 Therapy as of 2025)
Table 11. Global Market Short-acting GLP-1 Therapy Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers’ Manufacturing Sites, Areas Served
Table 13. Manufacturers’ Product Type
Table 14. Global Short-acting GLP-1 Therapy Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Short-acting GLP-1 Therapy Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Short-acting GLP-1 Therapy Sales by Type (K MT)
Table 27. Global Short-acting GLP-1 Therapy Market Size by Type (M USD)
Table 28. Global Short-acting GLP-1 Therapy Sales (K MT) by Type (2020-2025)
Table 29. Global Short-acting GLP-1 Therapy Sales Market Share by Type (2020-2025)
Table 30. Global Short-acting GLP-1 Therapy Market Size (M USD) by Type (2020-2025)
Table 31. Global Short-acting GLP-1 Therapy Market Share by Type (2020-2025)
Table 32. Global Short-acting GLP-1 Therapy Price (USD/KG) by Type (2020-2025)
Table 33. Global Short-acting GLP-1 Therapy Sales (K MT) by Application
Table 34. Global Short-acting GLP-1 Therapy Market Size by Application
Table 35. Global Short-acting GLP-1 Therapy Sales by Application (2020-2025) & (K MT)
Table 36. Global Short-acting GLP-1 Therapy Sales Market Share by Application (2020-2025)
Table 37. Global Short-acting GLP-1 Therapy Market Size by Application (2020-2025) & (M USD)
Table 38. Global Short-acting GLP-1 Therapy Market Share by Application (2020-2025)
Table 39. Global Short-acting GLP-1 Therapy Sales Growth Rate by Application (2020-2025)
Table 40. Global Short-acting GLP-1 Therapy Sales by Region (2020-2025) & (K MT)
Table 41. Global Short-acting GLP-1 Therapy Sales Market Share by Region (2020-2025)
Table 42. Global Short-acting GLP-1 Therapy Market Size by Region (2020-2025) & (M USD)
Table 43. Global Short-acting GLP-1 Therapy Market Size by Region (2020-2025)
Table 44. North America Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K MT)
Table 45. North America Short-acting GLP-1 Therapy Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K MT)
Table 47. Europe Short-acting GLP-1 Therapy Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Short-acting GLP-1 Therapy Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Short-acting GLP-1 Therapy Market Size by Region (2020-2025) & (M USD)
Table 50. South America Short-acting GLP-1 Therapy Sales by Country (2020-2025) & (K MT)
Table 51. South America Short-acting GLP-1 Therapy Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Short-acting GLP-1 Therapy Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Short-acting GLP-1 Therapy Market Size by Region (2020-2025) & (M USD)
Table 54. Global Short-acting GLP-1 Therapy Production (K MT) by Region(2020-2025)
Table 55. Global Short-acting GLP-1 Therapy Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Short-acting GLP-1 Therapy Revenue Market Share by Region (2020-2025)
Table 57. Global Short-acting GLP-1 Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Short-acting GLP-1 Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Short-acting GLP-1 Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Short-acting GLP-1 Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Short-acting GLP-1 Therapy Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Sanofi Basic Information
Table 63. Sanofi Short-acting GLP-1 Therapy Product Overview
Table 64. Sanofi Short-acting GLP-1 Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Sanofi Business Overview
Table 66. Sanofi SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. AstraZeneca Basic Information
Table 69. AstraZeneca Short-acting GLP-1 Therapy Product Overview
Table 70. AstraZeneca Short-acting GLP-1 Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. AstraZeneca Business Overview
Table 72. AstraZeneca SWOT Analysis
Table 73. AstraZeneca Recent Developments
Table 74. Amneal Pharmaceuticals Basic Information
Table 75. Amneal Pharmaceuticals Short-acting GLP-1 Therapy Product Overview
Table 76. Amneal Pharmaceuticals Short-acting GLP-1 Therapy Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Amneal Pharmaceuticals Business Overview
Table 78. Amneal Pharmaceuticals SWOT Analysis
Table 79. Amneal Pharmaceuticals Recent Developments
Table 80. Global Short-acting GLP-1 Therapy Sales Forecast by Region (2026-2035) & (K MT)
Table 81. Global Short-acting GLP-1 Therapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 82. North America Short-acting GLP-1 Therapy Sales Forecast by Country (2026-2035) & (K MT)
Table 83. North America Short-acting GLP-1 Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 84. Europe Short-acting GLP-1 Therapy Sales Forecast by Country (2026-2035) & (K MT)
Table 85. Europe Short-acting GLP-1 Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 86. Asia Pacific Short-acting GLP-1 Therapy Sales Forecast by Region (2026-2035) & (K MT)
Table 87. Asia Pacific Short-acting GLP-1 Therapy Market Size Forecast by Region (2026-2035) & (M USD)
Table 88. South America Short-acting GLP-1 Therapy Sales Forecast by Country (2026-2035) & (K MT)
Table 89. South America Short-acting GLP-1 Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 90. Middle East and Africa Short-acting GLP-1 Therapy Sales Forecast by Country (2026-2035) & (Units)
Table 91. Middle East and Africa Short-acting GLP-1 Therapy Market Size Forecast by Country (2026-2035) & (M USD)
Table 92. Global Short-acting GLP-1 Therapy Sales Forecast by Type (2026-2035) & (K MT)
Table 93. Global Short-acting GLP-1 Therapy Market Size Forecast by Type (2026-2035) & (M USD)
Table 94. Global Short-acting GLP-1 Therapy Price Forecast by Type (2026-2035) & (USD/KG)
Table 95. Global Short-acting GLP-1 Therapy Sales (K MT) Forecast by Application (2026-2035)
Table 96. Global Short-acting GLP-1 Therapy Market Size Forecast by Application (2026-2035) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Short-acting GLP-1 Therapy
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Short-acting GLP-1 Therapy Market Size (M USD), 2025-2035
Figure 5. Global Short-acting GLP-1 Therapy Market Size (M USD) (2020-2035)
Figure 6. Global Short-acting GLP-1 Therapy Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Short-acting GLP-1 Therapy Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Short-acting GLP-1 Therapy Product Life Cycle
Figure 13. Short-acting GLP-1 Therapy Sales Share by Manufacturers in 2025
Figure 14. Global Short-acting GLP-1 Therapy Revenue Share by Manufacturers in 2025
Figure 15. Short-acting GLP-1 Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Short-acting GLP-1 Therapy Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Short-acting GLP-1 Therapy Revenue in 2025
Figure 18. Industry Chain Map of Short-acting GLP-1 Therapy
Figure 19. Global Short-acting GLP-1 Therapy Market PEST Analysis
Figure 20. Global Short-acting GLP-1 Therapy Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Short-acting GLP-1 Therapy Market Share by Type
Figure 27. Sales Market Share of Short-acting GLP-1 Therapy by Type (2020-2025)
Figure 28. Sales Market Share of Short-acting GLP-1 Therapy by Type in 2025
Figure 29. Market Share of Short-acting GLP-1 Therapy by Type (2020-2025)
Figure 30. Market Share of Short-acting GLP-1 Therapy by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Short-acting GLP-1 Therapy Market Share by Application
Figure 33. Global Short-acting GLP-1 Therapy Sales Market Share by Application (2020-2025)
Figure 34. Global Short-acting GLP-1 Therapy Sales Market Share by Application in 2025
Figure 35. Global Short-acting GLP-1 Therapy Market Share by Application (2020-2025)
Figure 36. Global Short-acting GLP-1 Therapy Market Share by Application in 2025
Figure 37. Global Short-acting GLP-1 Therapy Sales Growth Rate by Application (2020-2025)
Figure 38. Global Short-acting GLP-1 Therapy Sales Market Share by Region (2020-2025)
Figure 39. Global Short-acting GLP-1 Therapy Market Size by Region (2020-2025)
Figure 40. North America Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Short-acting GLP-1 Therapy Sales Market Share by Country in 2024
Figure 43. North America Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Short-acting GLP-1 Therapy Market Size by Country in 2024
Figure 45. U.S. Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Short-acting GLP-1 Therapy Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Short-acting GLP-1 Therapy Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Short-acting GLP-1 Therapy Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Short-acting GLP-1 Therapy Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Short-acting GLP-1 Therapy Sales Market Share by Country in 2024
Figure 53. Europe Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Short-acting GLP-1 Therapy Market Size by Country in 2024
Figure 55. Germany Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Short-acting GLP-1 Therapy Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Short-acting GLP-1 Therapy Sales Market Share by Region in 2024
Figure 67. Asia Pacific Short-acting GLP-1 Therapy Market Size by Region in 2024
Figure 68. China Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Short-acting GLP-1 Therapy Sales and Growth Rate (K MT)
Figure 79. South America Short-acting GLP-1 Therapy Sales Market Share by Country in 2024
Figure 80. South America Short-acting GLP-1 Therapy Market Size and Growth Rate (M USD)
Figure 81. South America Short-acting GLP-1 Therapy Market Size by Country in 2024
Figure 82. Brazil Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Short-acting GLP-1 Therapy Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Short-acting GLP-1 Therapy Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Short-acting GLP-1 Therapy Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Short-acting GLP-1 Therapy Market Size by Region in 2024
Figure 92. Saudi Arabia Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Short-acting GLP-1 Therapy Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Short-acting GLP-1 Therapy Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Short-acting GLP-1 Therapy Production Market Share by Region (2020-2025)
Figure 103. North America Short-acting GLP-1 Therapy Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Short-acting GLP-1 Therapy Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Short-acting GLP-1 Therapy Production (K MT) Growth Rate (2020-2025)
Figure 106. China Short-acting GLP-1 Therapy Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Short-acting GLP-1 Therapy Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Short-acting GLP-1 Therapy Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Short-acting GLP-1 Therapy Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Short-acting GLP-1 Therapy Market Share Forecast by Type (2026-2035)
Figure 111. Global Short-acting GLP-1 Therapy Sales Forecast by Application (2026-2035)
Figure 112. Global Short-acting GLP-1 Therapy Market Share Forecast by Application (2026-2035)